33 results about "MiR-155" patented technology

The invention belongs to the field of biotechnologies, relates to an miRNA marker for diagnosis of breast cancer, application thereof and a diagnostic kit, provides an miRNA marker for diagnosis of breast cancer and application thereof to preparation of a breast cancer diagnosis kit and further provides a breast cancer diagnosis kit, wherein the contents of miR-146a, miR-155, Mir-21, miR-222 and miR-339 in tissues can be measured by the breast cancer diagnosis kit. The miRNA marker for diagnosis of breast cancer, application thereof and the diagnostic kit have the advantages that through a wide range of document surveys, tumor markers which possibly have potentials are screened out of documents which are published, through extensive experiments and analysis, five types of miRNA including miR-146a, miR-155, miR-21, miR-222 and miR-339 which have high diagnosis value on breast cancer are found, through development and application of the miRNA marker and the diagnostic kit, diagnosis of breast cancer can be more convenient and easier to conduct, a foundation is laid for rapidly and accurately grasping the patient condition by a clinical doctor, and help is provided for finding a novel small molecule drug target which has potential treatment value.

The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T_H17 and T_H1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells.

The invention discloses a miRNA marker associated with colorectal cancer metastasis in plasma and an application thereof and belongs to the technical fields of biotechnologies and medicine. The miRNAmarker associated with colorectal cancer metastasis in plasma is one or more of miR-96, miR-99b, miR-155, let-7a and let-7b. The specificity and sensitivity of the miRNA marker associated with colorectal cancer metastasis in plasma screened in the invention for predicting the colorectal cancer metastasis are obviously higher than those of a clinically used tumor marker CEA at present, and the diagnostic accuracy is greatly improved.

The invention discloses a miRNA marker relevant with colorectal cancer prognosis and application of the miRNA marker. The miRNA marker is miR-96 or miR-155 in plasma and is miR-99b in tissues. MiRNA which is relevant with colorectal cancer prognosis and screen by the invention can be taken a noninvasive marker for the colorectal cancer prognosis, and an important theoretical basis is provided forthe clinical application of miRNA.

The invention relates to the technical field of medical biology. Micro RNA-155 is micro ribonucleic acid (RNA) for regulating the maturation and natural immunoreaction of T cells and B cells. The invention provides a micro RNA-155-based plasmid for enhancing the immune effect of deoxyribonucleic acid (DNA) vaccine cells. A plasmid pcDNA 3.1-pre-miR-155 is obtained by inserting an expression sequence of a micro RNA-155 precursor molecule into a pcDNA-3.1 plasmid, and the micro RNA-155 precursor molecules can be expressed efficiently without influencing the expression capability of the co-transfected DNA vaccine. In an in-vivo test, the plasmid and the DNA vaccine are injected at the same time and have the capability of effectively introducing cellular immunoreaction, and such capability isrepresented by the increase of antigenically specific spleen IFN-gamma positive cells and enhancement of target killing capability of spleen CD8 positive cells. The plasmid of the invention can be added into the conventional DNA vaccine preparation and injected together so as to obviously promote the cellular immunoreaction induced by the DNA vaccine, and serves as a novel cell immune adjuvant.

The invention discloses a radionuclide marked microRNA-155 targeting probe for tumor imaging. According to the microRNA-155 targeting probe, the terminal 5' of a microRNA-155 targeting nucleic acid is connected with an amino acid by use of a hexyl; the nucleotidesequence of the microRNA-155 targeting nucleic acid is sequence 2 in the sequence table; the first to sixth nucleotides and the 18th to 23th nucleotides from the terminal 5' of the sequence 2 are all modified by sulfo groups, and the first to third nucleotides and the 21th to 23th nucleotides from the terminal 5' are all modified by 2'-methoxyls. The 99mTc-AAM-155 targeting probe can be effectively applied to vital tumor imaging, and also is capable of tracing the distribution situation in vivo of miR-155 at the vital level.

The invention relates to a method for preventing and treating atherosclerosis through inhibition of micro-RNA155. Specifically speaking, substantial rise of expression of miR-155 is positively correlated with severity of atherosclerosis; expression of miR-155 is greatly increased in peritoneal macrophages and serum of an atherosclerotic mouse (ApoE-/-/C57BL/6J), and oxLDL can specifically induce expression and secretion of miR-155 by the peritoneal macrophages of the mouse. In oxLDL-induced macrophages, rise of the expression level of miR-155 promotes phagocytosis of lipids and generation of active oxygen; an miR-155 inhibitor can substantially inhibit plaque formation in aorta abdominalis of the mouse; miR-155 is an important target in treatment of atherosclerotic diseases, and the miR-155 inhibitor can be used for prevention and treatment of atherosclerosis.

Disclosed in this specification is a method for predicting the prognosis of squamous cell lung cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-mir-146b, hsa-mir-191, hsa-mir-206, hsa-mir-299-3p, hsa-mir-155, hsa-mir-15a, hsa-mir-122a, hsa-mir-513, hsa-mir-184, hsa-mir-511, hsa- mir-100, hsa-mir-10a, hsa-mir-453, hsa-mir-379, hsa-mir-202, hsa-mir-21, hsa-mir-126, hsa-mir-494, hsa-mir-432, hsa-mir-370, and combinations of these sequences.

The invention discloses a miRNA biomarker and a detection kit used for urethral carcinoma diagnosis. The miRNA biomarker consists of the following microRNAs: hsa-miR-384, hsa-miR-155-5p, hsa-miR-424-5p, hsa-miR-132-3p and hsa-miR-143-3p. According to the miRNA biomarker and the detection kit, the five microRNAs, including the hsa-miR-384, the hsa-miR-155-5p, the hsa-miR-424-5p, the hsa-miR-132-3p and the hsa-miR-143-3p, remarkable in urethral carcinoma and para-carcinoma tissue expression difference are subjected to serological expression analysis; and a result shows that the five miRNAs are stably expressed in serum, the expression of the miRNAs in the serum has very good consistency with tissues, the expression of the hsa-miR-384, the hsa-miR-155-5p and the hsa-miR-424-5p is down-regulated, and the expression of the hsa-miR-132-3p and the hsa-miR-143-3p is up-regulated. The five miRNAs can serve as biomarkers for the urethral carcinoma diagnosis, and the sensitivity and specificity of combined diagnosis are remarkably higher than those of single miRNA diagnosis.

Methods and compositions involving miR-122, miR-15b, miR-21, and miR-155, which are useful for the treatment of various diseases, such as cancers, are described. Further described are methods and compositions useful for increasing, activating, or regulating NK cells and surface antigens.

The invention discloses application of hsa-miRNA-155-5p (miR-155 for short) for preparing medicine for inhibiting human enterovirus 71 (EV71 for short). The molecular biological technology is used forimproving expression of miR-155 in cells after the cells are infected with EV71. The miR-155 can assemble protein PICALM through targeting phosphatidylinositol clathrin, and then copying of the EV71is inhibited. The application provides the theoretical and experiment basis for diagnosing and treating diseases such as hand-foot-and-mouth diseases caused by the EV71, and can be applied to development of the medicine for treating EV71 infection.

The invention relates to an application of a non-coding small RNA gene miR-155 in preparing a medicine for curing gastricism. The gastricism can be caused by helicobacter pylori infection. The miR-155is highly expressed in helicobacter pylori infected gastric epithelial cells and human gastric mucosa tissues; furthermore, after the gastric epithelial cells GES-1 are transfected by a miR-155 simulator or a miR-155 inhibitor respectively, the miR-155 simulator can obviously reduce the protein secretion level of inflammatory factor lnterleukin 8, and growth-related oncogene Alpha, thus indicating that the miR-155 can effectively inhibit inflammatory response related to the helicobacter pylori infection.

The invention discloses an miRNAs marker used for diagnosing carotid atherosclerotic plaques and applications thereof. The expression levels of miR-21, miR-155, miR-221 and miR-222 in an unstable plaque with cerebral infarction group, an unstable plaque group and a stable plaque group can be obviously enhanced compared with a healthy control group; the expression level of miR-126 in the unstable plaque with cerebral infarction group and the unstable plaque group can be obviously reduced compared with the stable plaque group; and the expression level of the miR-126 in the unstable plaque with cerebral infarction group can also be obviously reduced compared with the unstable plaque group. The above five miRNAs are closely related to the growth, instability and rupture evolution processes ofthe plaques, so that the marker can be applied to the assessment of the stability of carotid atherosclerotic plaques and the screening of cerebral apoplexy high-risk population.

The invention relates to a method for preparing an RNA (ribonucleic acid) probe by using an miR-155 precursor as a template. The method comprises the following steps: designing at least one pair of primers according to the sequence of the miR-155 precursor, wherein the PCR (polymerase chain reaction) amplification product of the primers is a multiplex DNA (deoxyribonucleic acid) segment, and the multiplex DNA (deoxyribonucleic acid) segment can comprise all target sequences; carrying out PCR amplification on the miR-155 precursor cDNA (complementary deoxyribonucleic acid) plasmid by adopting the primers in the step A to obtain the multiplex DNA segment, purifying, and mixing to obtain the template; adding an RNA polymerase and a biotin-labeled UTP (uridine triphosphate) to react, doping UTP into the product, and purifying to obtain the RNA probe. The cRNA (complementary ribonucleic acid) probe can be completely covered on all the target sequences. The probe preparation method simplifies the probe preparation steps, and greatly shortens the whole experimental time. The probe has the advantages of higher specificity, higher stability, weaker background signals and higher sensitivity. On such basis, the invention provides a kit for quickly detecting pancreatic-cancer-related miR-155 expression.

The present invention relates to a method of detecting Hand-Foot-and-Mouth Disease (HMFD) in subjects. In particular, the method relates to detecting promising biomarkers in the saliva of these subjects. In an aspect of the present invention, there is provided a method for detecting HFMD, the method comprising determining the presence of a microRNA (miRNA) in a saliva sample, wherein the presenceof the miRNA in the saliva sample is indicative of HFMD. Preferably, the miRNA is any one selected from the group consisting of mir-18b, mir-125a, mir-145, mir-155, mir-221, mir-324, mir- 335 and further comprises mir-23a and mir-142.

The current disclosure relates to therapeutic treatments and diagnostic methods for esophageal cancer based on the expression level of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, said method comprising: diagnosing the patient with esophageal cancer when the patient is determined to have an elevated or decreased level of expression of one or more miRNAs selected from mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i in a sample from a patient relative to the expression level of the one or more miRNAs in a control sample; and administering an effective amount of an esophageal treatment to the diagnosed patient.

The present invention provides an in vitro method for obtaining data useful for diagnosing a cardiomyopathy in a human subject, wherein the method comprises using, as an indicator, the expression levels, obtained from a biological sample isolated from the human subject, preferably a plasma sample, of one or more of the following miRNAs miR-721 and/or miR-155); and obtaining a result of the method by comparing the expression levels of said one or more miRNAs with a reference value or with the expression levels of a control, indicator of the absence of cardiomyopathy.

The present invention provides small RNA-based biomarkers for monitoring or detecting the pathogenesis and/or treatment process of IgA nephropathy, and the biomarkers are selected from the group consisting of miR-15a, miR-16, miR-21, miR-29a, miR-34a, miR-125b, miR-141, miR-148b, miR-155, miR-184, miR-192, miR-200a, miR-200b, miR-200c, miR-204, miR-205, miR-210 , miR-301a, and miR-429. The markerscan be used to well detect the course of treatment.